Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes

BACKGROUND: The aim of this work was to to evaluate the incidence and risk factors of adverse events (AEs), focusing on cardiovascular events (CVEs) and hypokalemia, in patients treated with abiraterone acetate (AA) and prednisone (PDN) outside clinical trials, and their association with survival ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Cavo, Alessia, Rubagotti, Alessandra, Zanardi, Elisa, Fabbroni, Chiara, Zinoli, Linda, Di Meglio, Antonio, Arboscello, Eleonora, Bellodi, Andrea, Spallarossa, Paolo, Cattrini, Carlo, Messina, Carlo, Boccardo, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784574/
https://www.ncbi.nlm.nih.gov/pubmed/29383035
http://dx.doi.org/10.1177/1758834017745819

Ejemplares similares

Ejemplares similares